Atrophic Gastritis Predicts the Risk of Gastric Cancer

ConditionAtrophic Gastritis

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-70

SponsorShanghai Jiao Tong University School of Medicine

About this trial

Despite declining incidence rates, gastric cancer (GC) ranks the fourth leading cause of cancer-related mortality and the fifth most common cancer worldwide, with the highest incidence reported in Eastern Asia. The 5-year overall survival rate of early GC exceeds 90%, which was well above advanced GC. Most intestinal-type GCs follow the Correa cascade-inflammation,atrophy, intestinal metaplasia (IM), dysplasia and subsequent carcinoma. The presence of gastric mucosal atrophy and intestinal metaplasia are important risk factors for GC. The purpose of this study was to investigate the incidence of GC attributed to atrophic gastritis in a region with high incidence of GC.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Ability and willingness to participate in the study and to sign and give informed consent

Biopsies were collected based on the recommendation of updated Sydney system

Disqualifiers

under 18 or over 80 years old

history of gastrectomy

severe systemic diseases or malignancy

Trial population

Chronic gastritis diagnosed by routine endoscopic screening

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Esophagogastroscopy (OLGA 0-Ⅰ)
Other intervention
Surveillance endoscopies at years 3-5.
Esophagogastroscopy (OLGA II)
Other intervention
Surveillance endoscopies at years 2-3.
Esophagogastroscopy (OLGA III-IV)
Other intervention
Surveillance endoscopies every year.

Treatment groups

2,042 Participants

are divided into 3 treatment groups

Group A: OLGA 0-I1 intervention

Group B: OLGA II1 intervention

Group C: OLGA III-IV1 intervention

Trial outcomes

Primary outcomes

early gastric neoplasm

histological diagnosis of high-grade dysplasia, and adenocarcinoma.

Time frame

After the baseline endoscopy, participants were scheduled for surveillance endoscopies at years 3-5 for subjects with operative link on gastritis assessment (OLGA) 0-Ⅰ, at years 2-3 for subjects with OLGA II and 1 year for subjects with OLGA III-IV.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Shanghai Jiao Tong University School of Medicine

Lead sponsor

RenJi Hospital

Sponsor institution

Source ClinicalTrials.gov

Apply now